Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ten Years On, Access To Biosimilars Still Patchy in EU

Executive Summary

April saw the 10th anniversary of the first biosimilar approval in Europe –Sandoz International GMBH's Omnitrope (somatropin) – which was launched in 2006. But a decade on, even with 20 biosimilar products now available and many more to come as big biological drugs lose their patent protection, there are still significant barriers to biosimilar penetration and wide variations in patient access across the EU that need to be addressed.

You may also be interested in...



Biogen Adds To Biosimilar Anti-TNF Portfolio In Europe With Flixabi

Samsung Bioepis’s biosimilar infliximab, Flixabi, has been approved for marketing in Europe, where it will add to Biogen's marketed biosimilar TNF-inhibitor etanercept to give the company two cost-effective TNF-inhibitors to offer to patients and hard-pressed healthcare systems.

Biogen Adds To Biosimilar Anti-TNF Portfolio In Europe With Flixabi

Samsung Bioepis’s biosimilar infliximab, Flixabi, has been approved for marketing in Europe, where it will add to Biogen's marketed biosimilar TNF-inhibitor etanercept to give the company two cost-effective TNF-inhibitors to offer to patients and hard-pressed healthcare systems.

Tiny Mabion Races Big Pharma To EU Rituximab Market

Poland’s biotech Mabion is racing to the European biosimilar market with a biosimilar rituximab, but is up against multinational biosimilar companies like Sandoz and South Korea’s Celltrion, and will likely need a strong commercialization partner outside its home market.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID052006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel